439239-90-4 Usage
Description
Lasmiditan, also known as Item No. 28369, is an analytical reference standard that functions as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. It is primarily used in the treatment of migraine headaches and has been categorized under Schedule V regulation in the United States due to its low abuse potential. Lasmiditan is intended for research and forensic applications.
Uses
Used in Pharmaceutical Industry:
Lasmiditan is used as a pharmaceutical agent for the treatment of migraine headaches. It targets the serotonin (5-HT) receptor subtype 5-HT1F, providing relief from the symptoms associated with migraines.
Used in Research and Forensic Applications:
Lasmiditan is utilized as a research compound, aiding in the study of serotonin receptor subtype 5-HT1F and its role in migraine headaches. Additionally, it is employed in forensic applications, possibly for the analysis of its presence in biological samples or for the investigation of its potential misuse.
Used in Preventive Dentistry:
Lasmiditan is used as a preventive agent for periodontal disease and tooth loss. Although the specific mechanism of action in this context is not provided in the materials, it is likely that its agonistic effect on the 5-HT1F receptor may contribute to the prevention or management of these dental conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 439239-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,9,2,3 and 9 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 439239-90:
(8*4)+(7*3)+(6*9)+(5*2)+(4*3)+(3*9)+(2*9)+(1*0)=174
174 % 10 = 4
So 439239-90-4 is a valid CAS Registry Number.
439239-90-4Relevant articles and documents
Preparation method of lasmiditan
-
Paragraph 0091-0093, (2021/07/01)
The invention provides a preparation method of lasmiditan. Specifically, 2-bromo-6-aminopyridine is taken as a raw material and subjected to a condensation reaction with 2, 4, 6-trifluorobenzoyl chloride, and then the reaction product reacts with 1-methyl-4-ethyl piperidinecarboxylate to prepare the lasmiditan. The preparation method has the advantages of simple and safe synthesis route and operation, easily available raw materials, simple post-treatment and high yield, and is suitable for industrial production.
PROCESS FOR PREPARATION OF LASMIDITAN
-
, (2020/06/01)
The present invention relates to a process for the preparation of lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof, the process comprising reacting a compound of formula IX with N-methoxymethylamine or salt thereof to obtain a compound of formula VII; reacting the compound of formula VII with a compound of formula XIV to obtain lasmiditan or salts thereof.
CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
-
Paragraph 0252-0253, (2019/08/22)
The present invention relates to the crystalline forms of a 5-HT1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the presen